Chemoimmunotherapy: An emerging strategy for the treatment of malignant mesothelioma

Tissue Antigens

Volumn 74, Issue 1, 2009, Pages 1-10

  McCoy, M J ^a   Nowak, A K ^a   Lake, R A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Anticancer immune response; Chemotherapy; Immunotherapy; Malignant mesothelioma

Indexed keywords

BETA INTERFERON; CD40 LIGAND MONOCLONAL ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FGK 45; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PC 61; PEMETREXED; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LOW DRUG DOSE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOSUPPRESSION; MESOTHELIOMA; NEOPLASMS, MESOTHELIAL;

EID: 66949146154     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01275.x     Document Type: Review

References (93)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005 : 353 : 1591 603.
2. Takahashi K. Asbestos-related diseases: time for technology sharing. Occup Med (Lond) 2008 : 58 : 384 5.
3. Lin RT, Takahashi K, Karjalainen A et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007 : 369 : 844 9.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 : 21 : 2636 44.
5. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957 : 1 : 841 7.
6. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974 : 82 : 99 106.
7. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974 : 183 : 534 6.
8. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994 : 1 : 447 56.
9. van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996 : 184 : 1781 90.
10. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 : 410 : 1107 11.
11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 : 3 : 991 8.
12. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007 : 117 : 1137 46.
13. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008 : 27 : 5932 43.
14. Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004 : 199 : 9 26. (Pubitemid 38736761)
15. Marzo AL, Lake RA, Lo D et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999 : 162 : 5838 45.
16. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008 : 320 : 674 7.
17. Hansen K, Mossman BT. Generation of superoxide (O2-.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 1987 : 47 : 1681 6.
18. Archer VE. Carcinogenicity of fibers and films: a theory. Med Hypotheses 1979 : 5 : 1257 62.
19. Wang Y, Faux SP, Hallden G et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 2004 : 25 : 173 8.
20. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer 1994 : 58 : 330 9.
21. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006 : 24 : 175 208.
22. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 : 77 : 1303 10.
23. Ram M, Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci 2007 : 1110 : 410 25.
24. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006 : 27 : 1086 95.
25. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990 : 63 : 245 7.
26. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997 : 57 : 3200 7.
27. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996 : 93 : 136 40.
28. Ho M, Hassan R, Zhang J et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005 : 11 : 3814 20.
29. Yen MJ, Hsu CY, Mao TL et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006 : 12 : 827 31.
30. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008 : 70 : 431 57.
31. Creaney J, Segal A, Sterrett G et al. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 2008 : 98 : 1562 9.
32. Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax 1998 : 53 : 915 8.
33. Xia C, Xu Z, Yuan X et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002 : 1 : 687 94.
34. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 : 313 : 1960 4.
35. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005 : 353 : 2654 66.
36. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 : 348 : 203 13.
37. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 : 10 : 942 9.
38. Perrone G, Ruffini PA, Catalano V et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008 : 44 : 1875 82.
39. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009 : 27 : 186 92.
40. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002 : 14 : 432 6.
41. Odaka M, Sterman DH, Wiewrodt R et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001 : 61 : 6201 12.
42. Sterman DH, Recio A, Carroll RG et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007 : 13 : 4456 66.
43. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994 : 12 : 881 922. (Pubitemid 24140434)
44. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996 : 184 : 747 52.
45. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 : 393 : 480 3.
46. Friedlander PL, Delaune CL, Abadie JM et al. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 2003 : 29 : 321 30.
47. Vonderheide RH, Flaherty KT, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007 : 25 : 876 83.
48. Rudge G, Barrett SP, Scott B, van Driel IR. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007 : 178 : 4089 96.
49. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005 : 5 : 397 405. (Pubitemid 40637831)
50. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972 : 26 : 239 57.
51. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003 : 170 : 4905 13.
52. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001 : 50 : 445 55.
53. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004 : 172 : 4599 608.
54. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007 : 204 : 49 55. (Pubitemid 46148755)
55. Collins JL, Kao MS. The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 1989 : 29 : 17 22. (Pubitemid 19097511)
56. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 1997 : 9 : 339 46.
57. Dummer W, Niethammer AG, Baccala R et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002 : 110 : 185 92.
58. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002 : 62 : 2353 8.
59. Wijayahadi N, Haron MR, Stanslas J, Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother 2007 : 19 : 176 723.
60. Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982 : 42 : 4862 6.
61. Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004 : 34 : 336 44.
62. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007 : 56 : 641 8.
63. van der Most RG, Currie AJ, Mahendran S et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2008.
64. Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 2008 : 180 : 6467 71.
65. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008 : 180 : 2967 80.
66. Vicari AP, Luu R, Zhang N et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009 : 58 : 615 28.
67. Anraku M, Cunningham KS, Yun Z et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008 : 135 : 823 9.
68. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001 : 7 : 3025 30.
69. Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008 : 14 : 2413 20.
70. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005 : 202 : 1691 701.
71. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007 : 13 : 54 61. (Pubitemid 46067386)
72. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007 : 13 : 1050 9.
73. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007 : 13 : 851 6.
74. Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001 : 61 : 3689 97.
75. Song CK, Han HD, Noh KH et al. Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol Ther 2007 : 15 : 1558 63.
76. Tseng CW, Hung CF, Alvarez RD et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008 : 14 : 3185 92.
77. Zhong H, Han B, Tourkova IL et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007 : 13 : 5455 62.
78. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003 : 63 : 4490 6.
79. Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005 : 23 : 8950 8.
80. Correale P, Tagliaferri P, Fioravanti A et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008 : 14 : 4192 9.
81. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002 : 20 (Suppl 4 A40 5.
82. So T, Takenoyama M, Mizukami M et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005 : 65 : 5945 52.
83. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001 : 7 : 1118 22.
84. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997 : 159 : 770 6.
85. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003 : 9 : 1269 74.
86. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001 : 1 : 142 50.
87. Takahashi H, Feuerhake F, Kutok JL et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res 2006 : 12 : 3265 71.
88. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 : 8 : 793 800. (Pubitemid 34887242)
89. Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004 : 24 : 229 37.
90. Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008 : 180 : 1535 44.
91. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006 : 24 : 5716 24.
92. Jackaman C, Bundell CS, Kinnear BF et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003 : 171 : 5051 63.
93. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008 : 44 : 46 53. (Pubitemid 350262830)